Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version)

Masatoshi Kudo, Masafumi Ikeda, Kazuomi Ueshima, Michiie Sakamoto, Shuichiro Shiina, Ryosuke Tateishi, Kazuhiro Nouso, Kiyoshi Hasegawa, Junji Furuse, Shiro Miyayama, Takamichi Murakami, Tatsuya Yamashita, Norihiro Kokudo

研究成果: Article査読

抄録

Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on hepatocellular carcinoma (HCC) by locoregional therapies, such as radiofrequency ablation or transarterial chemoembolization. Therefore, establishment of response evaluation criteria solely devoted to HCC is needed in clinical practice, as well as in clinical trials of HCC treatment, such as systemic therapies, which cause necrosis of the tumor. Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2021 by the Liver Cancer Study Group of Japan based on the 2019 version of RECICL, which was commonly used in Japan. The major revised points of the RECICL 2021 is inclusion of RECIST version 1.1 and modified RECIST as response evaluation criteria in systemic therapy for HCC. We hope this new treatment response criteria, RECICL, proposed by the Liver Cancer Study Group of Japan will benefit the HCC treatment response evaluation in the setting of daily clinical practice and clinical trials as well, not only in Japan, but also internationally.

本文言語English
ページ(範囲)329-336
ページ数8
ジャーナルHepatology Research
52
4
DOI
出版ステータスPublished - 2022 4月

ASJC Scopus subject areas

  • 肝臓学
  • 感染症

フィンガープリント

「Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル